top of page
SCIENTIFIC PUBLICATIONS
Selected Most Important Publications
Blood pressure control according to type 2 diabetes status. Ruilope LM, Ruiz-Hurtado G. Lancet Diabetes Endocrinol. 2022 Sep;10(9):612-613.
Prevention of cardiorenal damage: importance of albuminuria. Ruilope LM, Ortiz A, Lucia A, Miranda B, Alvarez-Llamas G, Barderas MG, Volpe M, Ruiz-Hurtado G, Pitt B. Eur Heart J. 2023 Apr 1;44(13):1112-1123.
The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. Navarro-García JA, Salguero-Bodes R, González-Lafuente L, Martín-Nunes L, Rodríguez-Sánchez E, Bada-Bosch T, Hernández E, Mérida-Herrero E, Praga M, Solís J, Arribas F, Bueno H, Kuro-O M, Fernández-Velasco M, Ruilope LM, Delgado C, Ruiz-Hurtado G. BMC Med. 2022 Jan 19;20(1):14.
Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca2+ handling. Navarro-García JA, Rueda A, Romero-García T, Aceves-Ripoll J, Rodríguez-Sánchez E, González-Lafuente L, Zaragoza C, Fernández-Velasco M, Kuro-O M, Ruilope LM, Ruiz-Hurtado G. Br J Pharmacol. 2020 Oct;177(20):4701-4719.
Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho. Vázquez-Sánchez S, Blasco A, Polo-Salguero M, Mourino-Álvarez L, Gil-Fernández M, Corbacho-Alonso N, Navarro-García JA, Mercado-García E, González-Lafuente L, Rodríguez-Sánchez E, González-Moreno D, Pérez-Gómez A, Matutano A, Vázquez J, López JA, Fernández-Velasco M, Barderas MG, Ruiz-Hurtado G. J Am Heart Assoc. 2026 Feb 17;15(4): e045175.
2026
2025
153. Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho. Vázquez-Sánchez S, Blasco A, Polo-Salguero M, Mourino-Álvarez L, Gil-Fernández M, Corbacho-Alonso N, Navarro-García JA, Mercado-García E, González-Lafuente L, Rodríguez-Sánchez E, González-Moreno D, Pérez-Gómez A, Matutano A, Vázquez J, López JA, Fernández-Velasco M, Barderas MG, Ruiz-Hurtado G. J Am Heart Assoc. 2026 Feb 17;15(4): e045175.
152. Towards a better prevention in cardio-kidney metabolic syndrome: Role of aldosterone and albuminuria. Ruilope LM, Pitt B, de la Sierra A, Ruiz-Hurtado G. Nefrologia (Engl Ed). 2025 Nov;45(9):501399.
151. Finerenone prevents renal damage by enhancing SDF-1α/CXCR4-mediated stem cell mobilization in experimental type 1 diabetic nephropathy. Palma-Guzmán P, Bragado-García E, Durán-Mateos E, Sanz-Gómez M, Overall C, Aranguez I, Mercado-García E, Ruiz-Hurtado G, Kreutz R, Plaza A, Merino JJ, Fernández-Alfonso MS.Biomed Pharmacother. 2025 Dec; 193:118727.
150. Finerenone: Evidence for benefit in Early Stages of Cardiovascular-Kidney-Metabolic Syndrome. Márquez DF, Ortiz A, González-Moreno D, Ruilope LM, Ruiz-Hurtado G. Cardiorenal Med. 2025 Sep 25:1-15.
149. Atrial Myopathy and Heart Failure: Immunomolecular Mechanisms and Clinical Implications. Gil Fernández M, Bueno Sen A, Cantolla Pablo P, Val Blasco A, Ruiz Hurtado G, Delgado C, Cubillos C, Boscá L, Fernández Velasco M.Int J Mol Sci. 2025 Aug 24;26(17):8210.
148. Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome. Guerrero-Mauvecin J, Villar-Gómez N, Miño-Izquierdo L, Povo-Retana A, Ramos AM, Ruiz-Hurtado G, Sanchez-Niño MD, Ortiz A, Sanz AB.Antioxidants (Basel). 2025 Jun 9;14(6):701.
147. Cardiovascular disease in women with early-onset preeclampsia: a matched case-control study. Domínguez Del Olmo P, Herraiz I, Villalaín C, De la Parte B, Rodríguez-Sánchez E, Ruiz-Hurtado G, Fernández-Friera L, Morales E, Ayala JL, Solís J, Galindo A.J Matern Fetal Neonatal Med. 2025 Dec;38(1):2459302.
146. Is Fibroblast Growth Factor (FGF)23 a Player or a Trigger in Atrial Fibrillation? Navarro-García JA, Wehrens XHT, Ruiz-Hurtado G. Eur J Prev Cardiol. 2025 Feb 6: zwaf053.
145. Recombinant Klotho administration after myocardial infarction reduces ischaemic injury and arrhythmias by blocking intracellular calcium mishandling and CaMKII activation. Vázquez-Sánchez S, Blasco A, Fernández-Corredoira P, Cantolla P, Mercado-García E, Rodríguez-Sánchez E, González-Lafuente L, Poveda J, González-Moreno D, Matutano A, Peribañez S, García-Consuegra I, Volpe M, Fernández-Velasco M, Ruilope LM, Ruiz-Hurtado G. J Pathol. 2025 Mar;265(3):342-356.
144. Artificial Intelligence-Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure. Guimarães P, Keller A, Böhm M, Lauder L, Fehlmann T, Ruilope LM, Vinyoles E, Gorostidi M, Segura J, Ruiz-Hurtado G, Staplin N, Williams B, de la Sierra A, Mahfoud F. Hypertension. 2025 Jan;82(1):46-56.
2024
143. Interleukin-6 as a prognostic marker in acute kidney injury and its klotho-dependent regulation. González-Lafuente L, Mercado-García E, Vázquez-Sánchez S, González-Moreno D, Boscá L, Fernández-Velasco M, Segura J, Kuro-O M, Ruilope LM, Liaño F, Ruiz-Hurtado G. Nefrologia (Engl Ed). 2024 Nov-Dec;44(6):818-829.
142. Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study. Rodríguez-Miguel A, Fernández-Fernández B, Ortiz A, Gil M, Rodríguez-Martín S, Ruiz-Hurtado G, Fernández-Antón E, Ruilope LM, de Abajo FJ.Pharmaceuticals (Basel). 2024 Sep 29;17(10):1299.
141. Urinary extracellular vesicles as a monitoring tool for renal damage in patients not meeting criteria for chronic kidney disease. Anfaiha-Sanchez M, Santiago-Hernandez A, Lopez JA, Lago-Baameiro N, Pardo M, Martin-Blazquez A, Vazquez J, Ruiz-Hurtado G, Barderas MG, Segura J, Ruilope LM, Martin-Lorenzo M, Alvarez-Llamas G.J Extracell Biol. 2024 Sep 17;3(9):e170.
140. The Urinary Glycopeptide Profile Differentiates Early Cardiorenal Risk in Subjects Not Meeting Criteria for Chronic Kidney Disease. Santiago-Hernandez A, Martin-Lorenzo M, Gómez-Serrano M, Lopez JA, Martin-Blazquez A, Vellosillo P, Minguez P, Martinez PJ, Vázquez J, Ruiz-Hurtado G, Barderas MG, Sarafidis P, Segura J, Ruilope LM, Alvarez-Llamas G.Int J Mol Sci. 2024 Jun 26;25(13):7005.
139. Donor-Dependent Variations in Systemic Oxidative Stress and Their Association with One-Year Graft Outcomes in Kidney Transplantation. Rodriguez-Sanchez E, Aceves-Ripoll J, Mercado-García E, Navarro-García JA, Andrés A, Aguado JM, Segura J, Ruilope LM, Fernández-Ruiz M, Ruiz-Hurtado G. Am J Nephrol. 2024;55(5):509-519.
138. Artificial Intelligence-Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure. Guimarães P, Keller A, Böhm M, Lauder L, Fehlmann T, Ruilope LM, Vinyoles E, Gorostidi M, Segura J, Ruiz-Hurtado G, Staplin N, Williams B, de la Sierra A, Mahfoud F. Hypertension. 2025 Jan;82(1):46-56.
137. Hypertension and the kidney: an update. Ruilope LM, Ortiz A, Ruiz-Hurtado G. Eur Heart J. 2024 May 7;45(17):1497-1499.
2023
135. Targeting the TWEAK-Fn14 pathway prevents dysfunction in cardiac calcium handling after acute kidney injury. Poveda J, González-Lafuente L, Vázquez-Sánchez S, Mercado-García E, Rodríguez-Sánchez E, García-Consuegra I, Sanz AB, Segura J, Fernández-Velasco M, Liaño F, Ruilope LM, Ruiz-Hurtado G. J Pathol. 2023 Dec;261(4):427-441.
134. Cardiovascular and renal health: Preeclampsia as a risk marker. Villalaín González C, Herraiz García I, Fernández-Friera L, Ruiz-Hurtado G, Morales E, Solís J, Galindo A. Nefrologia (Engl Ed). 2023 May-Jun;43(3):269-280.
133. Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation. Song J, Navarro-Garcia JA, Wu J, Saljic A, Abu-Taha I, Li L, Lahiri SK, Keefe JA, Aguilar-Sanchez Y, Moore OM, Yuan Y, Wang X, Kamler M, Mitch WE, Ruiz-Hurtado G, Hu Z, Thomas SS, Dobrev D, Wehrens XH, Li N. J Clin Invest. 2023 Oct 2;133(19): e167517.
132. Global Oxidative Status Is Linked to Calcific Aortic Stenosis: The Differences Due to Diabetes Mellitus and the Effects of Metformin. Corbacho-Alonso N, Rodríguez-Sánchez E, Sastre-Oliva T, Mercado-García E, Perales-Sánchez I, Juarez-Alia C, López-Almodovar LF, Padial LR, Tejerina T, Mourino-Alvarez L, Ruiz-Hurtado G, Barderas MG.Antioxidants (Basel). 2023 Apr 28;12(5):1024.
131. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, Ruiz-Hurtado G, Segura J, Baigent C, Williams B. Lancet. 2023 Jun 17;401(10393):2041-2050.
130. Partial Genetic Deletion of Klotho Aggravates Cardiac Calcium Mishandling in Acute Kidney Injury. González-Lafuente L, Navarro-García JA, Valero-Almazán Á, Rodríguez-Sánchez E, Vázquez-Sánchez S, Mercado-García E, Pineros P, Poveda J, Fernández-Velasco M, Kuro-O M, Ruilope LM, Ruiz-Hurtado G. Int J Mol Sci. 2023 Jan 10;24(2):1322.
129. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL. J Hypertens. 2023 Feb 1;41(2):295-302.
128. Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration. Ruilope LM, Ruiz-Hurtado G. Hipertens Riesgo Vasc. 2023 Apr-Jun;40(2):55-57.
127. Prevention of cardiorenal damage: importance of albuminuria. Ruilope LM, Ortiz A, Lucia A, Miranda B, Alvarez-Llamas G, Barderas MG, Volpe M, Ruiz-Hurtado G, Pitt B. Eur Heart J. 2023 Apr 1;44(13):1112-1123.
2022
126. Hypertension mediated kidney and cardiovascular damage and risk stratification: Redefining concepts. Márquez DF, Rodríguez-Sánchez E, de la Morena JS, Ruilope LM, Ruiz-Hurtado G. Nefrologia (Engl Ed). 2022 Sep-Oct;42(5):519-530.
125. Imbalance in Bone Morphogenic Proteins 2 and 7 Is Associated with Renal and Cardiovascular Damage in Chronic Kidney Disease. Manzano-Lista FJ, Sanz-Gómez M, González-Moreno D, Vega-Martín E, Gil-Ortega M, Schulz A, Rubio MÁ, Ruiz-Hurtado G, Ruilope LM, Aránguez I, Kreutz R, Fernández-Alfonso MS.Int J Mol Sci. 2022 Dec 20;24(1):40.
124. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M, Nowack C, Kolkhof P, Joseph A, Bakris GL.J Hypertens. 2023 Feb 1;41(2):295-302.
123. Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration. Ruilope LM, Ruiz-Hurtado G. Hipertens Riesgo Vasc. 2023 Apr-Jun;40(2):55-57.
122. Rationale and Protocol of the Multimodality Evaluation of Antibody-Mediated Injury in Heart Transplantation (LEONE-HT) Observational Cross-Sectional Study. Nuche J, de la Cruz Bertolo J, Marco Clement I, Sánchez VS, Sarnago Cebada F, Mancebo E, Enguita AB, Alonso-Riaño M, Ruiz-Hurtado G, López-Azor JC, Hernández-Pérez FJ, Castrodeza J, Sánchez González J, Arribas Ynsaurriaga F, García-Cosío Carmena MD, Delgado JF.Methods Protoc. 2022 Sep 25;5(5):75.
121. Klotho relieves inflammation and exerts a cardioprotective effect during renal ischemia/reperfusion-induced cardiorenal syndrome. Junho CVC, González-Lafuente L, Neres-Santos RS, Navarro-García JA, Rodríguez-Sánchez E, Ruiz-Hurtado G, Carneiro-Ramos MS.Biomed Pharmacother. 2022 Sep;153:113515.
120. Blood pressure control according to type 2 diabetes status. Ruilope LM, Ruiz-Hurtado G. Lancet Diabetes Endocrinol. 2022 Sep;10(9):612-613.
119. Specialized Proresolving Mediators Protect Against Experimental Autoimmune Myocarditis by Modulating Ca2+ Handling and NRF2 Activation. Val-Blasco A, Prieto P, Jaén RI, Gil-Fernández M, Pajares M, Domenech N, Terrón V, Tamayo M, Jorge I, Vázquez J, Bueno-Sen A, Vallejo-Cremades MT, Pombo-Otero J, Sanchez-García S, Ruiz-Hurtado G, Gómez AM, Zaragoza C, Crespo-Leiro MG, López-Collazo E, Cuadrado A, Delgado C, Boscá L, Fernández-Velasco M.JACC Basic Transl Sci. 2022 May 18;7(6):544-560.
118. Editorial: Contribution of Uremic Compounds to Cardiorenal Syndrome Development. Carneiro-Ramos MS, Ruiz-Hurtado G, Vieyra A. Front Physiol. 2022 May 18 ;13:877182.
117. Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. Yanucil C, Kentrup D, Campos I, Czaya B, Heitman K, Westbrook D, Osis G, Grabner A, Wende AR, Vallejo J, Wacker MJ, Navarro-Garcia JA, Ruiz-Hurtado G, Zhang F, Song Y, Linhardt RJ, White K, Kapiloff MS, Faul C.Kidney Int. 2022 Aug;102(2):261-279.
116. Unilateral Acute Renal Ischemia-Reperfusion Injury Induces Cardiac Dysfunction through Intracellular Calcium Mishandling. Junho CVC, González-Lafuente L, Navarro-García JA, Rodríguez-Sánchez E, Carneiro-Ramos MS, Ruiz-Hurtado G. Int J Mol Sci. 2022 Feb 18;23(4):2266.
115. Use of chronic kidney disease blind spot to prevent cardiorenal outcomes. Ruilope LM, Ruiz-Hurtado G, Miranda B, Ortiz A. Eur Heart J. 2022 Jan 31;43(4):257-260.
114. Interplay between mineral bone disorder and cardiac damage in acute kidney injury: from Ca2+ mishandling and preventive role of Klotho in mice to its potential mortality prediction in human. González-Lafuente L, Navarro-García JA, Rodríguez-Sánchez E, Aceves-Ripoll J, Poveda J, Vázquez-Sánchez S, Mercado-García E, Fernández-Velasco M, Kuro-O M, Liaño F, Ruilope LM, Ruiz-Hurtado G. Transl Res. 2022 May; 243:60-77.
113. Murine models of uremic cardiomyopathy as a necessary tool to unravel mechanisms involved in cardiorenal syndrome. Navarro-García JA, Ruiz-Hurtado G. Kidney Int. 2022 Feb;101(2):214-216.
112. The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. Navarro-García JA, Salguero-Bodes R, González-Lafuente L, Martín-Nunes L, Rodríguez-Sánchez E, Bada-Bosch T, Hernández E, Mérida-Herrero E, Praga M, Solís J, Arribas F, Bueno H, Kuro-O M, Fernández-Velasco M, Ruilope LM, Delgado C, Ruiz-Hurtado G. BMC Med. 2022 Jan 19;20(1):14.
111. Editorial commentary: Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. Ruilope LM, Ruiz-Hurtado G, Tamargo J.Trends Cardiovasc Med. 2022 May;32(4):234-236.
110. Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, González-Lafuente L, Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Barderas MG, Segura J, Ruilope LM, Ruiz-Hurtado G. Eur Heart J Cardiovasc Pharmacother. 2022 Jan 5;8(1):68-76.
2021
109. Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets. Navarro-García JA, González-Lafuente L, Fernández-Velasco M, Ruilope LM, Ruiz-Hurtado G. Front Physiol. 2021 Nov 15; 12:775029.
108. Preventing and managing hypertension: do not forget the night. Ruilope LM, Ruiz-Hurtado G, Lucia A.Hypertens Res. 2021 Dec;44(12):1674-1675.
107. TCA Cycle and Fatty Acids Oxidation Reflect Early Cardiorenal Damage in Normoalbuminuric Subjects with Controlled Hypertension. Santiago-Hernandez A, Martin-Lorenzo M, Martin-Blazquez A, Ruiz-Hurtado G, Barderas MG, Segura J, Ruilope LM, Alvarez-Llamas G.Antioxidants (Basel). 2021 Jul 9;10(7):1100.
106. Early renal and vascular damage within the normoalbuminuria condition. Santiago-Hernandez A, Martin-Lorenzo M, Martínez PJ, Gómez-Serrano M, Lopez JA, Cannata P, Esteban V, Heredero A, Aldamiz-Echevarria G, Vázquez J, Ruiz-Hurtado G, Barderas MG, Segura J, Ruilope LM, Alvarez-Llamas G. J Hypertens. 2021 Nov 1;39(11):2220-2231.
105. May Measurement Month 2019: an analysis of blood pressure screening results from Spain. Molinero A, Calvo E, Beaney T, Day E, Prats-Mas R, Fornos JA, Mera-Gallego I, Tous S, de Andrés NF, Rodilla E, Gijón T, Pérez-Manchon D, Poulter NR, Ruiz-Hurtado G, Ruilope LM. Eur Heart J Suppl. 2021 May 20;23(Suppl B):B138-B140.
104. CARDIOVASCULAR RISK STRATIFICATION BASED ON OXIDATIVE STRESS FOR EARLY DETECTION OF PATHOLOGY. Corbacho-Alonso N, Baldan-Martin M, Lopez JA, Rodriguez- Sanchez E, Martinez PJ, Mourino-Alvarez L, Sastre-Oliva T, Cabrera M, Calvo E, Padial LR, Vazquez J, Vivanco F, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG. Antioxid Redox Signal. 2021 May 26.
103. Ca2+ mishandling in heart failure: potential targets. Val-Blasco A, Gil-Fernández M, Rueda A, Pereira L, Delgado C, Smani T, Ruiz Hurtado G, Fernández-Velasco M. Acta Physiol (Oxf). 2021 May 22:e13691.
102. ADEQUATE BLOOD PRESSURE CONTROL UNATTAINABLE WITHOUT ADEQUATE RECOGNITION AND TREATMENT OF PRIMARY ALDOSTERONISM. Ruilope LM, Ruiz-Hurtado G, Tamargo J. Trends Cardiovasc Med. 2021 Apr 16:S1050-1738(21)00047-5.
101. An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. Vázquez-Sánchez S, Poveda J, Navarro-García JA, González-Lafuente L, Rodríguez-Sánchez E, Ruilope LM, Ruiz-Hurtado G. Front Physiol. 2021 Mar 9;12:632260.
100. TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome. Poveda J, Vázquez-Sánchez S, Sanz AB, Ortiz A, Ruilope LM, Ruiz-Hurtado G. J Pathol. 2021 Jan 29. doi: 10.1002/path.5631.
99. Analysis of global oxidative status using multimarker scores reveals a specific association between renal dysfunction and diuretic therapy in older adults. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, González-Lafuente L, Corbacho-Alonso N, Baldan-Martín M, Madruga F, Alvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G. J Gerontol A Biol Sci Med Sci. 2021 Jan 10:glab012.
98. Lifestyle interventions for the prevention and treatment of hypertension. Valenzuela PL, Carrera-Bastos P, Gálvez BG, Ruiz-Hurtado G, Ordovas JM, Ruilope LM, Lucia A. Nat Rev Cardiol. 2021 Apr;18(4):251-275.
2020
97. Are the guidelines of the ISH devoted to a population not contemplated in the ACC/AHA guidelines? Ruilope LM, Ruiz-Hurtado G, Lucia A. Int J Cardiol Hypertens. 2020 Nov 18;7:100068.
96. Systemic lupus erythematosus and cardiovascular disease. Ruilope LM, Ruiz-Hurtado G. Int J Cardiol Hypertens. 2020 Nov 3;7:100065.
95. Age and blood pressure goal in women with prior coronary events. Ruilope LM, Ruiz-Hurtado G. Int J Cardiol Hypertens. 2020 Oct 20;7:100059.
94. Exercise Reduces Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Saco-Ledo G, Valenzuela PL, Ruiz-Hurtado G, Ruilope LM, Lucia A. J Am Heart Assoc. 2020 Dec 15;9(24):e018487.
93. Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca2+ Alterations in Adult Ventricular Cardiomyocytes. Rodríguez-Sánchez E, Navarro-García JA, González-Lafuente L, Aceves-Ripoll J, Vázquez-Sánchez S, Poveda J, Mercado-García E, Corbacho-Alonso N, Calvo-Bonacho E, Fernández-Velasco M, Álvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G. Antioxidants (Basel). 2020 Dec 1;9(12):1213.
92. Genetic Deletion of NOD1 Prevents Cardiac Ca2+ Mishandling Induced by Experimental Chronic Kidney Disease. Gil-Fernández M, Navarro-García JA, Val-Blasco A, González-Lafuente L, Martínez JC, Rueda A, Tamayo M, Morgado JL, Zaragoza C, Ruilope LM, Delgado C, Ruiz-Hurtado G, Fernández-Velasco M. Int J Mol Sci. 2020 Nov 23;21(22):8868.
91. Editorial: Evolving Picture of Calcium Handling in Cardiac Disease. Ruiz-Hurtado G, Rueda A, Pereira L, Fernández-Velasco M. Front Physiol. 2020 Sep 4;11:1013.
90. Urinary metabolic signatures reflect cardiovascular risk in the young, middle-aged, and elderly populations. Martinez PJ, Agudiez M, Molero D, Martin-Lorenzo M, Baldan-Martin M, Santiago-Hernandez A, García-Segura JM, Madruga F, Cabrera M, Calvo E, Ruiz-Hurtado G, Barderas MG, Vivanco F, Ruilope LM, Alvarez-Llamas G. J Mol Med (Berl). 2020 Nov;98(11):1603-1613.
89. Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca2+ handling. Navarro-García JA, Rueda A, Romero-García T, Aceves-Ripoll J, Rodríguez-Sánchez E, González-Lafuente L, Zaragoza C, Fernández-Velasco M, Kuro-O M, Ruilope LM, Ruiz-Hurtado G. Br J Pharmacol. 2020 Oct;177(20):4701-4719.
88. Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, González-Lafuente L, Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Barderas MG, Segura J, Ruilope LM, Ruiz-Hurtado G. Eur Heart J Cardiovasc Pharmacother. 2020 Jul 14:pvaa086.
86. Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life. Corbacho-Alonso N, Baldán-Martín M, López JA, Rodríguez-Sánchez E, Martínez PJ, Mourino-Alvarez L, Martin-Rojas T, Sastre-Oliva T, Madruga F, Vázquez J, Padial LR, Alvarez-Llamas G, Vivanco F, Ruiz-Hurtado G, Ruilope LM, Barderas MG. J Proteomics. 2020 Jun 30;222:103816.
84. Variations in Circulating Active MMP-9 Levels During Renal Replacement Therapy. Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, Abarca-Zabalía J, Susmozas-Sánchez A, Bada-Bosch T, Hernández E, Mérida-Herrero E, Andrés A, Praga M, Fernández-Ruiz M, Aguado JM, Segura J, Ruilope LM, Ruiz-Hurtado G. Biomolecules. 2020 Mar 26;10(4):505.
83. Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure. Tamayo M, Martín-Nunes L, Val-Blasco A, G M-Piedras MJ, Navarro-García JA, Lage E, Prieto P, Ruiz-Hurtado G, Fernández-Velasco M, Delgado C. Br J Pharmacol. 2020 Jul;177(14):3273-3290.
81. Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Frömter Rats, a Genetic Model of Chronic Kidney Disease. Gil-Ortega M, Vega-Martín E, Martín-Ramos M, González-Blázquez R, Pulido-Olmo H, Ruiz-Hurtado G, Schulz A, Ruilope LM, Kolkhof P, Somoza B, Kreutz R, Fernández-Alfonso MS. Am J Nephrol. 2020;51(4):294-303.
80. Early Posttransplant Mobilization of Monocytic Myeloid-derived Suppressor Cell Correlates With Increase in Soluble Immunosuppressive Factors and Predicts Cancer in Kidney Recipients. Utrero-Rico A, Laguna-Goya R, Cano-Romero F, Chivite-Lacaba M, Gonzalez-Cuadrado C, Rodríguez-Sánchez E, Ruiz-Hurtado G, Serrano A, Fernández-Ruiz M, Justo I, González E, Andrés A, Paz-Artal E. Transplantation. 2020 Dec;104(12):2599-2608.
78. Intracellular calcium mishandling leads to cardiac dysfunction and ventricular arrhythmias in a mouse model of propionic acidemia. Tamayo M, Fulgencio-Covián A, Navarro-García JA, Val-Blasco A, Ruiz-Hurtado G, Gil-Fernández M, Martín-Nunes L, Lopez JA, Desviat LR, Delgado C, Richard E, Fernández-Velasco M. Biochim Biophys Acta Mol Basis Dis. 2020 Jan 1;1866(1):165586.
2019
76. Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration. Navarro-García JA, Rodríguez-Sánchez E, Aceves-Ripoll J, Abarca-Zabalía J, Susmozas-Sánchez A, González Lafuente L, Bada-Bosch T, Hernández E, Mérida-Herrero E, Praga M, Ruilope LM, Ruiz-Hurtado G. Nutrients. 2019 Nov 17;11(11):2809.
73. Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors. RodrÍguez-SÁnchez E, Navarro-GarcÍa JA, Aceves-Ripoll J, GonzÁlez-Lafuente L, Corbacho-Alonso N, Martinez P, Calvo-Bonacho E, Alvarez-Llamas G, Barderas MG, Ruilope LM, Ruiz-Hurtado G. Transl Res. 2019 Oct;212:54-66.
72. Proteomic investigations into hypertension: what's new and how might it affect clinical practice? Corbacho-Alonso N, Rodríguez-Sánchez E, Martin-Rojas T, Mouriño-Alvarez L, Sastre-Oliva T, Hernandez-Fernandez G, Padial LR, Ruilope LM, Ruiz-Hurtado G, Barderas MG. Expert Rev Proteomics. 2019 Jul;16(7):583-591.
71. Monotherapy still useful in a bunch of patients with arterial hypertension. Ruilope LM, Ruiz-Hurtado G. Int J Cardiol. 2019 Sep 15;291:119-120.
70. Impact of the new USA and ESC/ESH HTN guidelines for Spain. Ruilope LM, Ruiz-Hurtado G. Eur Heart J. 2019 Jun 1;40(21):1660-1661.
69. Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. Ruilope LM, Ruiz-Hurtado G, Barderas MG, de la Cruz JJ, Lucia A, de la Sierra A, Gorostidi M, Vinyoles E, Segura J, Solís J, Arribas F, García-Puig J, Tamargo J, O'Brien E, Volpe M, Whelton PK, Williams B, Banegas JR. Hypertension. 2019 Jul;74(1):130-136.
67. Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension. Martin-Lorenzo M, Martinez PJ, Baldan-Martin M, Lopez JA, Minguez P, Santiago-Hernandez A, Vazquez J, Segura J, Ruiz-Hurtado G, Vivanco F, Barderas MG, Ruilope LM, Alvarez-Llamas G. Hypertension. 2019 Apr;73(4):794-802.
66. Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention. Martínez PJ, Baldán-Martín M, López JA, Martín-Lorenzo M, Santiago-Hernández A, Agudiez M, Cabrera M, Calvo E, Vázquez J, Ruiz-Hurtado G, Vivanco F, Ruilope LM, Barderas MG, Alvarez-Llamas G. Atherosclerosis. 2019 Mar;282:67-74.
64. Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson's Disease Patients. Yakhine-Diop SMS, Niso-Santano M, Rodríguez-Arribas M, Gómez-Sánchez R, Martínez-Chacón G, Uribe-Carretero E, Navarro-García JA, Ruiz-Hurtado G, Aiastui A, Cooper JM, López de Munaín A, Bravo-San Pedro JM, González-Polo RA, Fuentes JM. Mol Neurobiol. 2019 Apr;56(4):2466-2481.
62. Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. Navarro-García JA, Delgado C, Fernández-Velasco M, Val-Blasco A, Rodríguez-Sánchez E, Aceves-Ripoll J, Gómez-Hurtado N, Bada-Bosch T, Mérida-Herrero E, Hernández E, Praga M, Salguero R, Solís J, Arribas F, Delgado JF, Bueno H, Kuro-O M, Ruilope LM, Ruiz-Hurtado G. Nephrol Dial Trasp. 2019 Jan 19. doi: 10.1093/ndt/gfy392
2018
61. Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression. Baldan-Martin M, Rodríguez-Sánchez E, González-Calero L, Ruilope LM, Alvarez-Llamas G, Barderas MG, Ruiz-Hurtado G. Clin Sci (Lond). 2018 Apr 6;132(7):739-758. See Pubmed
60. Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. Baldan-Martin M, Lopez JA, Corbacho-Alonso N, Martinez PJ, Rodriguez-Sanchez E, Mourino-Alvarez L, Sastre-Oliva T, Martin-Rojas T, Rincón R, Calvo E, Vazquez J, Vivanco F, Padial LR, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG. Sci Rep. 2018 Mar 19;8(1):4802. See Pubmed
59. Specific Activation of the Alternative Cardiac Promoter of Cacna1c by the Mineralocorticoid Receptor. Mesquita TR, Auguste G, Falcón D, Ruiz-Hurtado G, Salazar-Enciso R, Sabourin J, Lefebvre F, Viengchareun S, Kobeissy H, Lechène P, Nicolas V, Fernandez-Celis A, Gómez S, Lauton Santos S, Morel E, Rueda A, López-Andrés N, Gómez AM, Lombès M, Benitah JP. Circ Res. 2018 Mar 30;122(7):e49-e61. See Pubmed
58. PTH, vitamin D, and the FGF-23-klotho axis and heart: going beyond the confines of nephrology. Navarro-García JA, Fernández-Velasco M, Delgado C, Delgado JF, Kuro-O M, Ruilope LM, Ruiz-Hurtado G. Eur J Clin Invest. 2018 Feb 2. 2018 Apr;48(4). See Pubmed
2017
57. Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension. Ruiz-Hurtado G, Ruilope LM. Eur Heart J. 2017 Nov 21;38(44):3318-3320. See Pubmed
56. Citric Acid Metabolism in Resistant Hypertension: Underlying Mechanisms and Metabolic Prediction of Treatment Response. Martin-Lorenzo M, Martinez PJ, Baldan-Martin M, Ruiz-Hurtado G, Prado JC, Segura J, de la Cuesta F, Barderas MG, Vivanco F, Ruilope LM, Alvarez-Llamas G. Hypertension. 2017 Nov;70(5):1049-1056.
See Pubmed
55. Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria. Martin-Lorenzo M, Gonzalez-Calero L, Martinez PJ, Baldan-Martin M, Lopez JA, Ruiz-Hurtado G, de la Cuesta F, Segura J, Vazquez J, Vivanco F, Barderas MG, Ruilope LM, Alvarez-Llamas G. Sci Rep. 2017 21;7(1):8894. Original.
See Pubmed
54. Rapid, automated and specific immunoassay to directly measure MMP-9-TIMP-1 interactions in human plasma using AlphaLISA technology: a new alternative to classical ELISA. Pulido-Olmo H, Rodríguez-Sánchez E, Navarro-García JA, Barderas MG, Álvarez-Llamas G, Segura J, Fernández-Alfonso MS, Ruilope LM, Ruiz-Hurtado G. Frontiers in Immunology. 2017 24;8:853. Original.
See Pubmed
53. Proteomic Analysis of Blood Extracellular Vesicles in Cardiovascular Disease by LC- MS/MS Analysis. Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Ruiz-Hurtado G, Ruilope LM, Barderas MG. Methods Mol Biol. 2017;1619:141-149.
See Pubmed
52. Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria. Gonzalez-Calero L, Martínez PJ, Martin-Lorenzo M, Baldan-Martin M, Ruiz-Hurtado G, de la Cuesta F, Calvo E, Segura J, Lopez JA, Vázquez J, Barderas MG, Ruilope LM, Vivanco F, Alvarez-Llamas G. Oncotarget. 2017 May 11. doi: 10.18632/oncotarget.17787. Original.
See Pubmed
51. The impact of antihypertensives on kidney disease. Marquez DF, Ruiz-Hurtado G, Ruilope L. F1000Res. 2017 May 2;6:611. eCollection 2017. Review.
See Pubmed
50. Has the SPRINT trial introduced a new blood-pressure goal in hypertension? Ruiz-Hurtado G, Banegas JR, Sarafidis PA, Volpe M, Williams B, Ruilope LM. Nat Rev Cardiol. 2017 May 11.
See Pubmed
49. Microvascular injury and the kidney in hypertension. Ruiz-Hurtado G, Ruilope LM. Hipertens Riesgo Vasc. 2017 Apr 18. pii: S1889-1837(17)30021-1. Editorial.
See Pubmed
48. Sacubitril/valsartan in the treatment of arterial hypertension: an unaccomplished promise? Ruiz-Hurtado G, Ruilope LM. Hypertens Res. 2017 May;40(5):439-440. Editorial.
See Pubmed
47. Mild and Short-Term Caloric Restriction Prevents Obesity-Induced Cardiomyopathy in Young Zucker Rats without Changing in Metabolites and Fatty Acids Cardiac Profile. Ruiz-Hurtado G, García-Prieto CF, Pulido-Olmo H, Velasco-Martín JP, Villa-Valverde P, Fernández-Valle ME, Boscá L, Fernández-Velasco M, Regadera J, Somoza B, Fernández-Alfonso MS. Front Physiol. 2017 Feb 1;8:42. eCollection 2017. Original.
See Pubmed
46. Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria. de la Cuesta F, Baldan-Martin M, Moreno-Luna R, Alvarez-Llamas G, Gonzalez-Calero L, Mourino-Alvarez L, Sastre-Oliva T, López JA, Vázquez J, Ruiz-Hurtado G, Segura J, Vivanco F, Ruilope LM, Barderas MG. Oncotarget. 2017 Feb 28;8(9):15553-15562. Original.
See Pubmed
45. Role of NOD1 in Heart Failure Progression via Regulation of Ca2+ Handling. Val-Blasco A, Piedras MJ, Ruiz-Hurtado G, Suarez N, Prieto P, Gonzalez-Ramos S, Gómez-Hurtado N, Delgado C, Pereira L, Benito G, Zaragoza C, Domenech N, Crespo-Leiro MG, Vasquez-Echeverri D, Nuñez G, Lopez-Collazo E, Boscá L, Fernández-Velasco M. J Am Coll Cardiol. 2017 Jan 31;69(4):423-433. Original.
See Pubmed
44. 24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients. Vinyoles E, de la Sierra A, Roso-Llorach A, Banegas JR, de la Cruz JJ, Gorostidi M, Segura J, Divisón JA, Ruíz-Hurtado G, Ruilope LM; Spanish ABPM Registry Investigators. J Hypertens. 2017 May;35(5):1011-1018. Original.
See Pubmed
2016
43. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Sarafidis PA, Lazaridis AA, Ruiz-Hurtado G, Ruilope LM. Nat Rev Endocrinol. 2017 Jun;13(6):365-374. Review.
See Pubmed
42. Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality? Ruiz-Hurtado G, Vigil L, Ruilope LM. Hipertens Riesgo Vasc. 2016 Oct - Dec;33(4):123-125. Editorial.
See Pubmed
41. Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. Ruiz-Hurtado G, Ruilope LM, de la Sierra A, Sarafidis P, de la Cruz JJ, Gorostidi M, Segura J, Vinyoles E, Banegas JR. Diabetes Care. 2016 Oct;39(10):1729-37. Original.
See Pubmed
40. Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progression. Gonzalez-Calero L, Martin-Lorenzo M, Martínez PJ, Baldan-Martin M, Ruiz-Hurtado G, Segura J, de la Cuesta F, Barderas MG, Ruilope LM, Vivanco F, Alvarez-Llamas G. Transl Res. 2016 Dec;178:25-37.e7. Original.
See Pubmed
39. Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators. Baldan-Martin M, Mourino-Alvarez L, Gonzalez-Calero L, Moreno-Luna R, Sastre-Oliva T, Ruiz-Hurtado G, Segura J, Lopez JA, Vazquez J, Vivanco F, Alvarez-Llamas G, Ruilope LM, de la Cuesta F, Barderas MG. Hypertension. 2016 Jul;68(1):157-66. Original.
See Pubmed
38. Global cardiovascular protection in chronic kidney disease. Ruiz-Hurtado G, Sarafidis P, Fernández-Alfonso MS, Waeber B, Ruilope LM. Nat Rev Cardiol. 2016 Oct;13(10):603-8. Review.
See Pubmed
37. Cardiovascular risk study in patients with renin-angiotensin system blockade by means of the proteone of circulating extracellular vesicles. de la Cuesta F, Baldan-Martin M, Mourino-Alvarez L, Sastre-Oliva T, Alvarez-Llamas G, Gonzalez-Calero L, Ruiz-Hurtado G, Segura J, Vivanco F, Ruilope LM, Barderas MG. Hipertens Riesgo Vasc. 2016 Jan-Mar;33(1):21-7. Original.
See Pubmed
36. Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. Gonzalez-Calero L, Martin-Lorenzo M, de la Cuesta F, Maroto AS, Baldan-Martin M, Ruiz-Hurtado G, Pulido-Olmo H, Segura J, Barderas MG, Ruilope LM, Vivanco F, Alvarez-Llamas G. Cardiovasc Diabetol. 2016 Jan 16;15:8. Original.
See Pubmed
35. Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. Pulido-Olmo H, García-Prieto CF, Álvarez-Llamas G, Barderas MG, Vivanco F, Aranguez I, Somoza B, Segura J, Kreutz R, Fernández-Alfonso MS, Ruilope LM, Ruiz-Hurtado G. Clin Sci (Lond). 2016 Apr 1;130(7):525-38. Original.
See Pubmed
34. New Strategy to Control Blood Pressure: Interactive Mobile Phone Support. Ruiz-Hurtado G, Ruilope LM. J Clin Hypertens (Greenwich). 2016 Feb;18(2):109-10. Editorial.
See Pubmed
2015
33. Salutary cardiovascular effects of antidiabetic drugs: myth or fact? Ruiz-Hurtado G, Ruilope LM. J Hypertens. 2015 Nov;33(11):2198-9. Editorial.
See Pubmed
32. An update of the blockade of the renin angiotensin aldosterone system in clinical practice. Márquez DF, Ruiz-Hurtado G, Ruilope LM, Segura J. Expert Opin Pharmacother. 2015;16(15):2283-92. Review.
See Pubmed
31. Ambulatory and home blood pressure monitoring in people with chronic kidney disease. Time to abandon clinic blood pressure measurements? Ruiz-Hurtado G, Gorostidi M, Waeber B, Ruilope LM. Curr Opin Nephrol Hypertens. 2015 Nov;24(6):488-91. Review.
See Pubmed
30. Reconciling depressed Ca2+ sparks occurrence with enhanced RyR2 activity in failing mice cardiomyocytes. Ruiz-Hurtado G, Li L, Fernández-Velasco M, Rueda A, Lefebvre F, Wang Y, Mateo P, Cassan C, Gellen B, Benitah JP, Gómez AM. J Gen Physiol. 2015 Oct;146(4):295-306. Original.See Pubmed
29. Fetal undernutrition is associated with perinatal sex-dependent alterations in oxidative status. Rodríguez-Rodríguez P, de Pablo AL, Condezo-Hoyos L, Martín-Cabrejas MA, Aguilera Y, Ruiz-Hurtado G, Gutierrez-Arzapalo PY, Ramiro-Cortijo D, Fernández-Alfonso MS, González Mdel C, Arribas SM. J Nutr Biochem. 2015 Dec;26(12):1650-9. Original.
See Pubmed
28. Proarrhythmic effect of sustained EPAC activation on TRPC3/4 in rat ventricular cardiomyocytes. Domínguez-Rodríguez A, Ruiz-Hurtado G, Sabourin J, Gómez AM, Alvarez JL, Benitah JP. J Mol Cell Cardiol. 2015 Oct;87:74-8. Original.
See Pubmed
27. Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics. Baldan-Martin M, de la Cuesta F, Alvarez-Llamas G, Gonzalez-Calero L, Ruiz-Hurtado G, Moreno-Luna R, Mourino-Alvarez L, Sastre-Oliva T, Segura J, Padial LR, Vivanco F, Ruilope LM, Barderas MG. Int J Cardiol. 2015 Oct 1;196:170-7. Original
See Pubmed
26. 8D.08: Matrix metalloproteinase (MMP) 2 and MMP9 activity is increased in conditionsof albuminuria escape under chronic renin-angiotensinsystem suppression. Pulido-Olmo H, Gracia-Prieto CF, Somoza B, Aránguez I, Alvarez-Llamas G, Vivanco F, Barderas MG, Kreutz R, Segura J, Fernández-Alfonso MS, Ruilope LM, Ruiz-Hurtado G. J Hypertens. 2015 Jun;33 Suppl 1:e115-6.
See Pubmed
25. Genetic predisposition to albuminuria is associated with increased arterial stiffness: role of elastin. Gil-Ortega M, García-Prieto CF, Ruiz-Hurtado G, Steireif C, González MC, Schulz A, Kreutz R, Fernández-Alfonso MS, Arribas S, Somoza B. Br J Pharmacol. 2015 Sep;172(17):4406-18. Original.
See Pubmed
24. NOD1, a new player in cardiac function and calcium handling. Delgado C, Ruiz-Hurtado G, Gómez-Hurtado N, González-Ramos S, Rueda A, Benito G, Prieto P, Zaragoza C, Delicado EG, Pérez-Sen R, Miras-Portugal MT, Núñez G, Boscá L, Fernández-Velasco M. Cardiovasc Res. 2015 Jun 1;106(3):375-86. Original.
See Pubmed
23. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. Ruiz-Hurtado G, Ruilope LM. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):126-31. Review.
See Pubmed
22. Mild caloric restriction reduces blood pressure and activates endothelial AMPK-PI3K-Akt-eNOS pathway in obese Zucker rats. García-Prieto CF, Pulido-Olmo H, Ruiz-Hurtado G, Gil-Ortega M, Aranguez I, Rubio MA, Ruiz-Gayo M, Somoza B, Fernández-Alfonso MS. Vascul Pharmacol. 2015 Feb-Mar;65-66:3-12. Original.
See Pubmed
21. High-fat diet induces endothelial dysfunction through a down-regulation of the endothelial AMPK-PI3K-Akt-eNOS pathway. García-Prieto CF, Hernández-Nuño F, Rio DD, Ruiz-Hurtado G, Aránguez I, Ruiz-Gayo M, Somoza B, Fernández-Alfonso MS. Mol Nutr Food Res. 2015 Mar;59(3):520-32. Original.
See Pubmed
2014
20. Ca(2+) handling alterations and vascular dysfunction in diabetes. Fernández-Velasco M, Ruiz-Hurtado G, Gómez AM, Rueda A. Cell Calcium. 2014 Nov;56(5):397-407. Review.
See Pubmed
19. Calcium signaling in diabetic cardiomyocytes. Pereira L, Ruiz-Hurtado G, Rueda A, Mercadier JJ, Benitah JP, Gómez AM. Cell Calcium. 2014 Nov;56(5):372-80. Review.
See Pubmed
18. Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. Ruiz-Hurtado G, Condezo-Hoyos L, Pulido-Olmo H, Aranguez I, Del Carmen Gónzalez M, Arribas S, Cerezo C, Segura J, Praga M, Fernández-Alfonso MS, Ruilope LM. J Hypertens. 2014 Oct;32(10):2082-91; discussion 2091. Original.
See Pubmed
17. Does cardiovascular protection translate into renal protection? Ruiz-Hurtado G, Ruilope LM. Nat Rev Cardiol. 2014 Dec;11(12):742-6. Review.
See Pubmed
16. Hypertension and obesity: correlates with renin-angiotensin-aldosterone system and uric acid. Ruiz-Hurtado G, Ruilope LM. J Clin Hypertens (Greenwich). 2014 Aug;16(8):559-60. Editorial.
See Pubmed
2013
15. Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy. Gómez AM, Ruiz-Hurtado G, Benitah JP, Domínguez-Rodríguez A. Curr Vasc Pharmacol. 2013 Jul;11(4):497-506. Review.
14. Dissecting the genetic predisposition to albuminuria and endothelial dysfunction in a genetic rat model. Steireif C, García-Prieto CF, Ruiz-Hurtado G, Pulido-Olmo H, Aranguez I, Gil-Ortega M, Somoza B, Schönfelder G, Schulz A, Fernández-Alfonso MS, Kreutz R. J Hypertens. 2013 Nov;31(11):2203-12; discussion 2212. Original.
2012
2011
2010
2009
13. The other side of cardiac Ca(2+) signaling: transcriptional control. Domínguez-Rodríguez A, Ruiz-Hurtado G, Benitah JP, Gómez AM. Front Physiol. 2012 Nov 28;3:452. Review.
12. Epac in cardiac calcium signaling. Ruiz-Hurtado G, Morel E, Domínguez-Rodríguez A, Llach A, Lezoualc'h F, Benitah JP, Gomez AM. J Mol Cell Cardiol. 2013 May;58:162-71. Review.
11. Sustained Epac activation induces calmodulin dependent positive inotropic effect in adult cardiomyocytes. Ruiz-Hurtado G, Domínguez-Rodríguez A, Pereira L, Fernández-Velasco M, Cassan C, Lezoualc'h F, Benitah JP, Gómez AM. J Mol Cell Cardiol. 2012 Nov;53(5):617-25. Original.
10. Cardiotrophin-1 induces sarcoplasmic reticulum Ca(2+) leak and arrhythmogenesis in adult rat ventricular myocytes. Ruiz-Hurtado G, Gómez-Hurtado N, Fernández-Velasco M, Calderón E, Smani T, Ordoñez A, Cachofeiro V, Boscá L, Díez J, Gómez AM, Delgado C. Cardiovasc Res. 2012 Oct 1;96(1):81-9. Original.
9. Epac enhances excitation-transcription coupling in cardiac myocytes. Pereira L, Ruiz-Hurtado G, Morel E, Laurent AC, Métrich M, Domínguez-Rodríguez A, Lauton-Santos S, Lucas A, Benitah JP, Bers DM, Lezoualc'h F, Gómez AM. J Mol Cell Cardiol. 2012 Jan;52(1):283-91. Original.
8. RyRCa2+ leak limits cardiac Ca2+ window current overcoming the tonic effect of calmodulinin mice. Fernández-Velasco M, Ruiz-Hurtado G, Rueda A, Neco P, Mercado-Morales M, Delgado C, Napolitano C, Priori SG, Richard S, Gómez AM, Benitah JP. PLoS One. 2011;6(6):e20863. Original.
7. Cardioprotective action of urocortin in postconditioning involves recovery of intracellular calcium handling. Calderón-Sánchez EM, Ruiz-Hurtado G, Smani T, Delgado C, Benitah JP, Gómez AM, Ordóñez A. Cell Calcium. 2011 Jul;50(1):84-90. Original.
6. Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors. Ruiz-Hurtado G, Delgado C. J Hypertens. 2010 Sep;28 Suppl 1:S56-61. Review.
5. Urocortin induces positive inotropic effect in rat heart. Calderón-Sanchez E, Delgado C, Ruiz-Hurtado G, Domínguez-Rodríguez A, Cachofeiro V, Rodríguez-Moyano M, Gomez AM, Ordóñez A, Smani T. Cardiovasc Res. 2009 Sep 1;83(4):717-25. Original.
4. Cardiac L-type calcium current is increased in a model of hyperaldosteronism in the rat. Martin-Fernandez B, Miana M, De Las Heras N, Ruiz-Hurtado G, Fernandez-Velasco M, Bas M, Ballesteros S, Lahera V, Cachofeiro V, Delgado C. Exp Physiol. 2009 Jun;94(6):675-83. Original.
2007
3. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Ruiz-Hurtado G, Fernández-Velasco M, Mourelle M, Delgado C. Hypertension. 2007 Dec;50(6):1049-56. Original.
2. TNF-alpha downregulates transient outward potassium current in rat ventricular myocytes through iNOS overexpression and oxidant species generation. Fernández-Velasco M, Ruiz-Hurtado G, Hurtado O, Moro MA, Delgado C. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H238-45. Original.
2006
1. I K1 and I f in ventricular myocytes isolated from control and hypertrophied rat hearts. Fernández-Velasco M, Ruiz-Hurtado G, Delgado C. Pflugers Arch. 2006 May;452(2):146-54. Original.
Book Chapters:
1. HYPERTENSION IN LATIN/HISPANIC POPULATION. LM Ruilope; JR Banegas; Gema Ruiz-Hurtado. Hypertension: a Companion to Braunwald‘s Heart Disease. 2016.
2. CARDIACARRHYTHMIAS-NEW CONSIDERATIONS. Gema Ruiz-Hurtado; JL Álvarez; JP Benitah. L-type Ca2+ current in cardiac arrhythmias. INTECH. ISBN 978 953 51 0126 0. 2012.
bottom of page